Second try at protecting children against rotavirus gastroenteritis

Pediatricians are all too familiar with rotavirus infection: Estimates are that 2.7 million episodes of rotavirus gastroenteritis make babies-and their parents-miserable each year. Most affected children recover on their own, but approximately 250,000 suffer dehydration serious enough to necessitate a visit to the emergency room and as many as 70,000 of those end up hospitalized.

Ten years ago, when a rotavirus vaccine was approved by the FDA and included in the Recommended Childhood Immunization Schedule, it appeared that the rotavirus story might be headed for a happy ending. But that vaccine (RotaShield, Wyeth-Lederle) was withdrawn after less than a year because it appeared to be associated with an increased risk of bowel intussusception. Rotavirus infection once again seemed an inevitable winter visitor.

Last month, however, things began looking up again. Two new rotavirus vaccines, both effective and both apparently able to avoid an association with intussusception, have appeared on the scene:

Related Videos
Benjamin Maxwell, MD, chief of child and adolescent psychiatry, Rady Children’s Hospital, San Diego, California | Image provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx -
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe
Thomas R. Young, MD | Image Credit: Author provided
J. Thomas Megerian, MD, PhD, FAAP | Author provided
© 2023 MJH Life Sciences

All rights reserved.